STRO vs. FDMT, DNA, IMTX, AUTL, RLAY, INBX, HUMA, MESO, PRME, and SRRK
Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include 4D Molecular Therapeutics (FDMT), Ginkgo Bioworks (DNA), Immatics (IMTX), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Inhibrx (INBX), Humacyte (HUMA), Mesoblast (MESO), Prime Medicine (PRME), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
Sutro Biopharma (NASDAQ:STRO) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Sutro Biopharma has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.
4D Molecular Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Sutro Biopharma. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 3 mentions for Sutro Biopharma. 4D Molecular Therapeutics' average media sentiment score of 0.74 beat Sutro Biopharma's score of 0.45 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
Sutro Biopharma received 88 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 66.04% of users gave 4D Molecular Therapeutics an outperform vote while only 64.74% of users gave Sutro Biopharma an outperform vote.
97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 5.9% of Sutro Biopharma shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sutro Biopharma has a net margin of -74.61% compared to 4D Molecular Therapeutics' net margin of -436.30%. 4D Molecular Therapeutics' return on equity of -26.75% beat Sutro Biopharma's return on equity.
Sutro Biopharma currently has a consensus target price of $12.50, indicating a potential upside of 236.93%. 4D Molecular Therapeutics has a consensus target price of $45.63, indicating a potential upside of 100.81%. Given Sutro Biopharma's higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than 4D Molecular Therapeutics.
Summary
4D Molecular Therapeutics beats Sutro Biopharma on 11 of the 17 factors compared between the two stocks.
Get Sutro Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sutro Biopharma Competitors List
Related Companies and Tools
